Supernus Pharmaceuticals (SUPN) Stock Overview
A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SUPN Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Supernus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.33 |
| 52 Week High | US$40.28 |
| 52 Week Low | US$25.55 |
| Beta | 0.71 |
| 1 Month Change | -3.31% |
| 3 Month Change | 0.92% |
| 1 Year Change | 21.25% |
| 3 Year Change | 17.37% |
| 5 Year Change | 34.07% |
| Change since IPO | 501.96% |
Recent News & Updates
Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes
Jun 16Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality
May 13
Recent updates
Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes
Jun 16Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality
May 13Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking
Feb 10Supernus: New Approval Holds Promise Of Increased Growth
Feb 06Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Nov 12Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
Oct 31
Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics
Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Sep 12Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
Aug 19Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Jul 02Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Oct 10Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Aug 19Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear
Aug 16Supernus: A Work In Progress
Jul 29Shareholder Returns
| SUPN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.8% | -1.3% | -1.0% |
| 1Y | 21.2% | -9.0% | 9.8% |
Return vs Industry: SUPN exceeded the US Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: SUPN exceeded the US Market which returned 10.9% over the past year.
Price Volatility
| SUPN volatility | |
|---|---|
| SUPN Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: SUPN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SUPN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 674 | Jack Khattar | www.supernus.com |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea.
Supernus Pharmaceuticals, Inc. Fundamentals Summary
| SUPN fundamental statistics | |
|---|---|
| Market cap | US$2.03b |
| Earnings (TTM) | US$61.91m |
| Revenue (TTM) | US$668.00m |
Is SUPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUPN income statement (TTM) | |
|---|---|
| Revenue | US$668.00m |
| Cost of Revenue | US$77.36m |
| Gross Profit | US$590.64m |
| Other Expenses | US$528.72m |
| Earnings | US$61.91m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.99 |
| Gross Margin | 88.42% |
| Net Profit Margin | 9.27% |
| Debt/Equity Ratio | 0% |
How did SUPN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/17 17:55 |
| End of Day Share Price | 2025/06/17 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Bodnar | Berenberg |
| David Buck | B. Riley Securities, Inc. |
| John Tanner | Cantor Fitzgerald & Co. |